Adhera Therapeutics Inc Financials

ATRX

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2023 Currency USD FYE December

This page shows Adhera Therapeutics Inc (ATRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATRX FY2022 2026-04-22

Balance-sheet shrinkage left liabilities vastly larger than operating resources, making ATRX look financed by obligations rather than active business turnover.

From FY2018 to FY2022, cash fell from $3.9M to $32K while total liabilities were still $22.3M against just $79K of assets, so the company did not simply get smaller; liquidity evaporated much faster than obligations. The current ratio sliding from 2.1x to 0.0035x shows near-term claims now dominate the balance sheet.

FY2021 adds an earnings-quality clue: operating cash flow of -$665K was nearly the same as operating loss of -$674K, which means cash burn was basically the reported loss rather than a temporary working-capital swing. That points to a business with little noncash cushion left in its cost base.

The drop in shares outstanding from 15.6M in FY2021 to 3.2M in FY2022 did not repair solvency, because equity remained deeply negative at -$22.2M. With no reported operating scale in recent filings and only $32K of cash, capital structure matters more than operations in explaining the current financial picture.

Financial Health Signals

Financial health score pending refresh

We are recalculating Adhera Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$32K

YoY-57.9%

5Y CAGR-21.4%

10Y CAGR-17.4%

Adhera Therapeutics Inc held $32K in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

Adhera Therapeutics Inc had 3M shares outstanding in fiscal year 2022.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

$2K

Adhera Therapeutics Inc spent $2K on share buybacks in fiscal year 2022, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

ATRX Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	N/A	N/A	N/A	$252K+231.6%	$76K	N/A
Cost of Revenue	N/A	N/A	N/A	$409K+44.0%	$284K	N/A
Gross Profit	N/A	N/A	N/A	-$157K+24.5%	-$208K	N/A
R&D Expenses	N/A	N/A	N/A	$0-100.0%	$241K-73.4%	$907K
SG&A Expenses	N/A	$657K	N/A	N/A	$6.0M+27.4%	$4.7M
Operating Income	N/A	-$674K	N/A	N/A	-$15.8M-159.3%	-$6.1M
Interest Expense	N/A	N/A	N/A	$682K	N/A	N/A
Income Tax	N/A	N/A	N/A	$0	$0-100.0%	$800
Net Income	N/A	N/A	N/A	N/A	-$16.8M-169.4%	-$6.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$43K-85.5%	$296K-16.1%	$353K	N/A	$224K-50.1%	$449K+72.7%	$260K	N/A
Operating Income	N/A	-$296K+16.1%	-$353K	N/A	-$548K-22.0%	-$449K-72.7%	-$260K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	$271K	N/A	N/A	N/A	$98K+233.3%	-$74K	N/A
EPS (Diluted)	$-0.83-8200.0%	$-0.01	N/A	N/A	$-0.57	$-0.27	N/A	N/A

ATRX Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$79K-59.9%	$196K+19500.0%	$1K-99.8%	$420K-91.8%	$5.1M-16.9%	$6.2M
Current Assets	$79K-59.9%	$196K+19500.0%	$1K-99.8%	$420K-91.0%	$4.7M+3643.3%	$125K
Cash & Equivalents	$32K-57.9%	$76K+7500.0%	$1K-98.0%	$50K-98.7%	$3.9M+3583.1%	$106K
Inventory	N/A	N/A	N/A	$0-100.0%	$242K	N/A
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$48K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$3.5M
Total Liabilities	$22.3M-12.0%	$25.3M+71.6%	$14.7M+43.0%	$10.3M+365.5%	$2.2M-61.4%	$5.7M
Current Liabilities	$22.3M-12.0%	$25.3M+71.3%	$14.8M+43.3%	$10.3M+365.5%	$2.2M-61.4%	$5.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$22.2M+11.6%	-$25.1M-70.3%	-$14.7M-49.1%	-$9.9M-437.8%	$2.9M+553.3%	$448K
Retained Earnings	-$55.8M-5.2%	-$53.0M-18.8%	-$44.6M-13.4%	-$39.3M-52.1%	-$25.8M-221.9%	-$8.0M

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Total Assets	$44K-46.3%	$82K-21.2%	$104K+32.5%	$79K-69.3%	$256K-73.8%	$976K+474.1%	$170K-13.3%	$196K
Current Assets	$44K-46.3%	$82K-21.2%	$104K+32.5%	$79K-69.3%	$256K-73.8%	$976K+474.1%	$170K-13.3%	$196K
Cash & Equivalents	$32K-44.2%	$58K-15.9%	$69K+115.6%	$32K-75.9%	$133K-84.3%	$849K+2022.5%	$40K-47.4%	$76K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$26.4M+15.3%	$22.9M-1.4%	$23.2M+4.2%	$22.3M+0.9%	$22.1M+5.2%	$21.0M-18.3%	$25.7M+1.4%	$25.3M
Current Liabilities	$26.4M+15.3%	$22.9M-1.4%	$23.2M+4.2%	$22.3M+0.9%	$22.1M+5.2%	$21.0M-18.3%	$25.7M+1.4%	$25.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$26.3M-15.5%	-$22.8M+1.3%	-$23.1M-4.1%	-$22.2M-1.7%	-$21.8M-9.1%	-$20.0M+21.6%	-$25.5M-1.6%	-$25.1M
Retained Earnings	-$60.0M-6.3%	-$56.4M+0.4%	-$56.7M-1.6%	-$55.8M-0.7%	-$55.4M-3.4%	-$53.6M-0.2%	-$53.5M-0.8%	-$53.0M

ATRX Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	N/A	-$665K	N/A	N/A	-$9.6M-662.4%	-$1.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0+100.0%	-$74K+80.3%	-$375K
Financing Cash Flow	N/A	$739K	N/A	N/A	$13.5M+724.6%	$1.6M
Dividends Paid	N/A	N/A	N/A	$1.5M	N/A	N/A
Share Buybacks	$2K	N/A	N/A	$0-100.0%	$250K	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Operating Cash Flow	-$29K+90.8%	-$316K-1.9%	-$310K-425.1%	-$59K+91.1%	-$666K-40.5%	-$474K-119.4%	-$216K+27.0%	-$296K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4K-98.8%	$305K-12.1%	$347K+921.4%	-$42K+15.1%	-$50K-103.9%	$1.3M+612.8%	$180K-18.2%	$220K
Dividends Paid	$27K+1.1%	$27K+1.1%	$26K	N/A	$9K-95.7%	$202K-44.6%	$364K	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0	N/A	N/A	N/A

ATRX Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	-62.3%+211.4pp	-273.7%	N/A
Operating Margin	N/A	N/A	N/A	N/A	-20782.9%	N/A
Net Margin	N/A	N/A	N/A	N/A	-22046.0%	N/A
Return on Equity	N/A	N/A	N/A	N/A	-572.4%+815.8pp	-1388.3%
Return on Assets	N/A	N/A	N/A	N/A	-325.9%-225.3pp	-100.6%
Current Ratio	0.000.0	0.010.0	0.00-0.0	0.04-2.1	2.11+2.1	0.02
Debt-to-Equity	-1.000.0	-1.010.0	-1.00+0.0	-1.04-1.8	0.76-12.0	12.80
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	330.8%	N/A	N/A	N/A	10.1%+53.4pp	-43.4%	N/A
Current Ratio	0.000.0	0.000.0	0.000.0	0.000.0	0.01-0.0	0.05+0.0	0.010.0	0.01
Debt-to-Equity	-1.000.0	-1.000.0	-1.000.0	-1.000.0	-1.01+0.0	-1.05-0.0	-1.010.0	-1.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$22.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

GB Sciences GBLX

$81K

U S Stem Cell Inc USRM

$64K

Reneuron Group RNUGF

$63K

Syros Pharmaceut SYRS

$3.1M

Aridis Pharmaceuticals Inc ARDS

$4K

Frequently Asked Questions

What are Adhera Therapeutics Inc's total assets?

Adhera Therapeutics Inc (ATRX) had $79K in total assets as of fiscal year 2022, including both current and long-term assets.

Does Adhera Therapeutics Inc buy back shares?

Yes, Adhera Therapeutics Inc (ATRX) spent $2K on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.

How many shares does Adhera Therapeutics Inc have outstanding?

Adhera Therapeutics Inc (ATRX) had 3M shares outstanding as of fiscal year 2022.

What is Adhera Therapeutics Inc's current ratio?

Adhera Therapeutics Inc (ATRX) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Adhera Therapeutics Inc's debt-to-equity ratio?

Adhera Therapeutics Inc (ATRX) had a debt-to-equity ratio of -1.00 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Adhera Therapeutics Inc's debt-to-equity ratio negative or unusual?

Adhera Therapeutics Inc (ATRX) has negative shareholder equity of -$22.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.